THE TGA has published an Australian Public Assessment Report for prescription medicines (AusPAR) covering the evaluation process for Bristol-Myers Squibb's ipilimumab (rch) (Yervoy/Winglore) as first line therapy for melanoma.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 17
